Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News GlaxoSmithKline/Pfizer’s ViiV Healthcare receives CHMP backing for HIV drug

GlaxoSmithKline/Pfizer’s ViiV Healthcare receives CHMP backing for HIV drug

26th November 2013

GlaxoSmithKline and Pfizer's joint venture ViiV Healthcare has been granted a recommendation for EU approval of its new HIV therapy Tivicay.

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has endorsed the drug for use in combination with other antiretroviral medicinal products for the treatment of HIV-infected adults and adolescents above 12 years of age.

Positive data has been collected from four pivotal phase III studies, which involved patients from a variety of treatment backgrounds and included comparators representing antiretroviral treatments commonly used today to combat HIV.

A final marketing authorisation decision from the European Commission is now expected early in 2014.

Dr John Pottage, chief medical officer at ViiV Healthcare, said: "To make progress, thousands of patients have supported us through their participation in clinical development work and we recognise their commitment today with great gratitude."

This comes after GlaxoSmithKline and Pfizer announced earlier this month that they will be collaborating on the development of a new combination therapy for melanoma.ADNFCR-8000103-ID-801665008-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.